Company Profiles

driven by the PitchBook Platform

NOXXON Pharma

Description

Developer of non-immunogenic alternative to antibodies for the treatment of inflammatory diseases and hematological disorders. The company develops a therapeutics named Spiegelmers that is focused for the treatment of immune cells to the kidney in diabetic patients.

1997

Founded

PUBLIC

Status

11-50

Employees

IPO

Latest Deal Type

$117M

Total Amount Raised

Description

Developer of non-immunogenic alternative to antibodies for the treatment of inflammatory diseases and hematological disorders. The company develops a therapeutics named Spiegelmers that is focused for the treatment of immune cells to the kidney in diabetic patients.

Website:

www.noxxon.com

Ownership Status

Publicly held

Financing Status

Formerly VC-Backed

Primary Industry

Biotechnology

Primary Office

Max-Dohrn-Strasse 8-10 10589 BerlinGermany +49 (0)30 7262 470
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore NOXXON Pharma's full profile, request a free trial.

NOXXON Pharma Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

NOXXON Pharma Executive Team (3)

NameTitleBoard
Seat
Contact
Info
Aram Mangasarian Ph.DChief Executive Officer
Sven Klussmann Ph.DChief Scientific Officer & Founder
Matthias BaumannChief Medical Officer
Aram Mangasarian Ph.D Chief Executive Officer
Sven Klussmann Ph.D Chief Scientific Officer & Founder
Matthias Baumann Chief Medical Officer

NOXXON Pharma Board Members (4)

NameRepresentingRoleSinceContact
Info
Bertram KöhlerSelfBoard Member000 0000
Donald DeBethizy Ph.DSelfBoard Member000 0000
Lawrence Posner MDSelfBoard Member000 0000
Walter Wenninger Ph.DSelfChairman, Supervisory Board000 0000
Bertram Köhler Board Member Self
Donald DeBethizy Ph.D Board Member Self
Lawrence Posner MD Board Member Self
Walter Wenninger Ph.D Chairman, Supervisory Board Self
Request full access to PitchBook